SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008132
Filing Date
2023-05-04
Accepted
2023-05-04 16:30:56
Documents
44
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20230331x10q.htm   iXBRL 10-Q 811695
2 EX-31.1 plx-20230331xex31d1.htm EX-31.1 10025
3 EX-31.2 plx-20230331xex31d2.htm EX-31.2 10385
4 EX-32.1 plx-20230331xex32d1.htm EX-32.1 6119
5 EX-32.2 plx-20230331xex32d2.htm EX-32.2 6145
6 GRAPHIC plx-20230331x10q005.jpg GRAPHIC 113571
7 GRAPHIC plx-20230331x10q006.jpg GRAPHIC 100730
8 GRAPHIC plx-20230331x10q007.jpg GRAPHIC 34509
  Complete submission text file 0001558370-23-008132.txt   3556726

Data Files

Seq Description Document Type Size
9 EX-101.SCH plx-20230331.xsd EX-101.SCH 23752
10 EX-101.CAL plx-20230331_cal.xml EX-101.CAL 31315
11 EX-101.DEF plx-20230331_def.xml EX-101.DEF 96487
12 EX-101.LAB plx-20230331_lab.xml EX-101.LAB 168547
13 EX-101.PRE plx-20230331_pre.xml EX-101.PRE 151152
38 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230331x10q_htm.xml XML 298334
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 23889286
SIC: 2836 Biological Products, (No Diagnostic Substances)